Hcw biologics and wy biotech announce license agreement for immunotherapeutic product candidate

Hcw biologics entered into license, research and co-development agreement with wy biotech for one of its new proprietary preclinical molecules hcw biologics to receive upfront payment of $7 million and is eligible to receive additional milestone payments and double-digit royalties on future product sales miramar, fla., nov. 18, 2024 (globe newswire) -- hcw biologics inc. (“hcwb” or “hcw biologics”), (nasdaq: hcwb), a u.s.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and wy biotech co., ltd.
HCWB Ratings Summary
HCWB Quant Ranking